Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-09-30
2009-06-09
Balasubram, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S231500, C544S291000, C544S111000
Reexamination Certificate
active
07544690
ABSTRACT:
The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.
REFERENCES:
patent: WO 92/07844 (1992-05-01), None
patent: WO 97/20823 (1997-06-01), None
patent: WO 97/20822 (1997-12-01), None
Kowalski et al. Expert Opin. Investig. Drugs 13(9), 1113-1122, 2004.
Nahon, C. R. Biologies, 329, 623-638, 2006.
Elslager et al., Journal of Medicinal Chemistry, 24(2), 127-140, 1981.
Yukio Shimomura, et al., “Isolation and Identification of Melanin-Concentrating Hormone as the Endogenous Ligand of the SLC-1 Receptor,” Biochemical and Biophysical Research Communications, Aug. 11, 1999, pp. 622-626, vol. 261, No. 3, Aug. 11, 1999.
Yumiko Saito, et al., “Melanin-concentrating Hormone Receptor: An Orphan Receptor Fits the Key,” TEM, 2000, pp. 299-3-03, vol. 11, No. 8.
Beth Borowsky, et al., “Antidepressant, anxiolytic and anorectic effects of melanin-concentrating hormone-1 receptor antagonist,” Nature Medicine, Aug. 2002, pp. 825-830, vol. 8., No. 8.
Masako Shimada, et al., “Mice lacking melanin-concentrating hormone and hypophagic and lean,” Nature, Dec. 17, 1998, pp. 670-674, vol. 396.
Jay C. Erickson, et al., Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y, Nature, May 30, 1996, pp. 415-418, vol. 381.
Thierry Pedrazzini, “Cardiovascular response, feeding behavior and locomotor activity in mice lacking the NPY Y1 receptor,” Nature Medicine, Jun. 1998, pp. 722-726, vol. 4, No. 6.
Donald J. Marsh, et al., “Role of the Y5 neuropeptide Y receptor in feeding and obesity,” Nature Medicine, Jun. 1988, pp. 718-721, vol. 4, No. 6.
Health Implications of Obesity, “National Institutes of Health Consensus Development Conference Statement,” (online), originally published Feb. 1985, pp. 1-7, vol. 5, No. 9.
KM Flegal, MD, “Overweight and Obesity in the United States: prevalence and trends,” International Journal of Obesity, 1998, pp. 39-47, vol. 22.
Patsy M. Nishina, et al., “Atherosclerosis in Genetically Obese Mice: The Mutants Obese, Diabetes, Fat, Tubby, and Lethal Yellow,” Metabolism, May 1994, pp. 554-558, vol. 43, No. 5.
Beeley Nigel Robert Arnold
Kanuma Kosuke
Kramer Bryan Aubrey
Omodera Katsunori
Sekiguchi Yoshinori
Balasubram Venkataraman
Sughrue & Mion, PLLC
Taisho Pharmaceutical Co. Ltd.
LandOfFree
MCH receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MCH receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MCH receptor antagonists will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4098129